Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues:
Product sales	$ 10,213	$ 8,075	$ 27,788	$ 20,900
Lease income from a related party		37	60	110
Total revenues	10,213	8,112	27,848	21,010
Costs of revenues:
Costs of revenues	4,247	3,417	11,555	8,757
Gross Profit	5,966	4,695	16,293	12,253
Operating expenses:
Research and development	3,905	2,895	11,748	10,408
General and administrative	4,849	5,259	15,694	16,249
Selling and marketing	3,566	3,433	10,241	9,508
Acquired in-process research and development	0	0	0	6,555
Total operating expenses	12,320	11,587	37,683	42,720
Loss from operations	(6,354)	(6,892)	(21,390)	(30,467)
Non-operating income (expense):
Interest (expense)/income, net	(13)	79	101	261
Other income	11	487	60	540
Foreign exchange gains/(losses)	637	(6)	2,325	289
Change in fair value of investments	696	(3,687)	(2,012)	(205)
Impairment loss of long-term investments				(865)
Loss before income tax expense	(5,023)	(10,019)	(20,916)	(30,447)
Net loss	(5,023)	(10,019)	(20,916)	(30,447)
Less: loss attributable to redeemable noncontrolling interest	(738)	(314)	(1,703)	(980)
Accretion to redeemable noncontrolling interest redemption value	916	519	2,264	1,586
Net loss attributable to CASI Pharmaceuticals, Inc.	$ (5,201)	$ (10,224)	$ (21,477)	$ (31,053)
Net loss per share (basic)	$ (0.38)	$ (0.73)	$ (1.57)	$ (2.30)
Net loss per share (diluted)	$ (0.38)	$ (0.73)	$ (1.57)	$ (2.30)
Weighted average number of common stock outstanding (basic)	13,606,130	13,979,636	13,668,553	13,486,024
Weighted average number of common stock outstanding (diluted)	13,606,130	13,979,636	13,668,553	13,486,024
Comprehensive loss:
Net loss	$ (5,023)	$ (10,019)	$ (20,916)	$ (30,447)
Foreign currency translation adjustment	(3,127)	15	(6,420)	848
Total comprehensive loss	(8,150)	(10,004)	(27,336)	(29,599)
Less: Comprehensive loss attributable to redeemable noncontrolling interest	(2,074)	(309)	(4,218)	(712)
Comprehensive loss attributable to common stockholders	$ (6,076)	$ (9,695)	$ (23,118)	$ (28,887)